Eyepoint (EYPT) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Eyepoint in October 2026.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Eyepoint (EYPT) Stock Forecast
Analyst price target, next 12 months
$25.25
+6142.3% vs today's $0.40
Price range over the last 12 months
Close to its 12-month low
Analysts covering Eyepoint have a consensus 12-month target of $25.25, above the current price of $0.40.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 12 Aug 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding EYEPOINT's stock with a target price of $25.25, indicating possible growth.
Financial Health
Eypoint Inc is generating modest revenue and cash flow, with a reasonable gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
